Search

Your search keyword '"Díez Campelo M"' showing total 226 results

Search Constraints

Start Over You searched for: Author "Díez Campelo M" Remove constraint Author: "Díez Campelo M"
226 results on '"Díez Campelo M"'

Search Results

1. Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification—an approach to classification of patients with t-MDS

2. Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes.

4. Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC)

5. P118 - Topic: AS07-Singular Entities/Subtypes/AS07e-Chronic myelomonocytic leukemia and overlap syndromes (MDS/MPN): GENOMIC AND TRANSCRIPTOMIC CHARACTERIZATION OF MYELODYSPLASTIC SYNDROMES/MYELOPROLIFERATIVE NEOPLASMS

6. P091 - Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: A STEP TOWARDS IDENTIFICATION AND CAUSAL INTERPRETATION OF THERAPY-RELATED MDS (T-MDS)

8. P074 - Topic: AS04-MDS Biology and Pathogenesis/AS04h-Immune deregulation/inflammation: BONE MARROW MICROENVIRONMENT CHANGES IN MYELODYSPLASTIC NEOPLASMS AND ITS RELATIONSHIP WITH CLONAL HEMATOPOIESIS

9. P052 - Topic: AS04-MDS Biology and Pathogenesis/AS04d-Somatic mutations: TP53 ALLELIC STATE DID NOT INFLUENCE THE PROGNOSIS IN MYELODYSPLASTIC SYNDROMES (MDS) WITH 5Q DELETION

11. O10 - CHARACTERIZATION OF TRANSCRIPTIONAL ALTERATIONS LEADING TO ABERRANT MYELOID DIFFERENTIATION IN MYELODYSPLASTIC SYNDROMES

14. Incidence and prognostic impact of U2AF1 mutations and other gene alterations in myelodysplastic neoplasms with isolated 20q deletion.

16. P756: ALLOGENEIC STEM CELL TRANSPLANTATION IN MYELODYSPLASTIC SYNDROME/MYELOPROLIFERATIVE NEOPLASM (MDS/MPN) OVERLAP SYNDROMES. A SINGLE CENTER EXPERIENCE AND DISSECTION OF MUTATIONAL PROFILE

17. P788: FACTORS DRIVING TREATMENT DECISION IN PATIENTS WITH INTERMEDIATE-RISK MYELODYSPLASTIC SYNDROME (MDS): A RETROSPECTIVE ANALYSIS FROM THE GRUPO ESPAÑOL DE SÍNDROMES MIELODISPLÁSICOS SPANISH MDS REGISTRY

18. Multicenter Next-Generation Sequencing Studies between Theory and Practice: Harmonization of Data Analysis Using Real-World Myelodysplastic Syndrome Data

20. Immunophenotypic alterations of bone marrow myeloid cell compartments in multiple myeloma patients predict for myelodysplasia-associated cytogenetic alterations

23. P30 - Topic: AS04-MDS Biology and Pathogenesis/AS04h-Immune deregulation: RELATION BETWEEN INMUNE CELL POPULATIONS AND MALIGNANT CLONE MUTATIONAL STATUS IN MYELODYSPLASTIC SYNDROMES

25. O29 - Topic: AS02-Epidemiology: COMPARISON OF CYTOGENETIC ABERRATIONS IN 1590 PATIENTS WITH THERAPY-RELATED MDS (T-MDS) AND 4738 PATIENTS FROM THE REVISED INTERNATIONAL PROGNOSTIC SCORING SYSTEM DATABASE WITH PRIMARY-MDS (P-MDS)

26. O20 - Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: INCORPORATION OF COHESIN MUTATIONAL DATA INTO CURRENT IPSS-R CLASSIFICATION REFINES THE PROGNOSTIC STRATIFICATION OF VERY LOW/LOW-RISK MYELODYSPLASTIC SYNDROMES

27. Topic: AS02-Epidemiology

28. Topic: AS04-MDS Biology and Pathogenesis/AS04i-Microenvironment and stem cell niche

29. Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment

30. Topic: AS04-MDS Biology and Pathogenesis/AS04h-Immune deregulation

35. Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification—an approach to classification of patients with t-MDS

36. Chronic graft-versus-host disease could ameliorate the impact of adverse somatic mutations in patients with myelodysplastic syndromes and hematopoietic stem cell transplantation

37. MUTATIONS ON COHESIN COMPLEX ARE ASSOCIATED TO A POOR PROGNOSIS IN LOW-RISK MYELODYSPLASTIC SYNDROMES PATIENTS

38. S837 TREATMENT WITH IMETELSTAT PROVIDES DURABLE TRANSFUSION INDEPENDENCE (TI) IN HEAVILY TRANSFUSED NON-DEL(5Q) LOWER RISK MDS (LR-MDS) RELAPSED/REFRACTORY (R/R) TO ERYTHROPOIESIS STIMULATING AGENTS (ESAS)

39. PF541 TRANSCRIPTIONAL ALTERATIONS OF HEMATOPOIETIC STEM CELLS IN MYELODYSPLASTIC SYNDROMES

40. PF533 MUTATIONS ON COHESIN COMPLEX ARE ASSOCIATED TO A POOR PROGNOSIS IN LOW-RISK MYELODYSPLASTIC SYNDROMES PATIENTS

42. TRANSCRIPTIONAL ALTERATIONS OF HEMATOPOIETIC STEM CELLS IN MYELODYSPLASTIC SYNDROMES

43. 41 - Chronic GVHD Could Ameliorate the Impact of Adverse Somatic Mutations in Patients with Myelodysplastic Syndromes and Hematopoietic Stem Cell Transplantation

44. Erythroleukemia shares biological features and outcome with myelodysplastic syndromes with excess blasts: a rationale for its inclusion into future classifications of myelodysplastic syndromes

45. Chronic GVHD Could Ameliorate the Impact of Adverse Somatic Mutations in Patients with Myelodysplastic Syndromes and Hematopoietic Stem Cell Transplantation

46. Mutational Status of Mesenchymal Stem Cell in Myelodysplastic Syndromes Patients

47. Mutational and Clonal Dynamics During Progression from MDS to SAML by Whole-Exome and Targeted-Deep Sequencing

48. Sintra-Rev Clinical Trial: Preliminary Analysis of Efficacy and Safety at Week 12 of Treatment in MDS Del(5Q) and Transfusion Independence

49. What is the Outcome of Patients in the Intermediate IPSS-R Score Group? Spanish Approach for Better Stratification with Classical Tools

50. DNA Repair Genes Transcriptome in Chronic Myelomonocytic Leukemia

Catalog

Books, media, physical & digital resources